From: Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
Publication
Number of patients
Overall response rate, percentage
Complete remission, percentage
Ganem et al. (1994) [3]
27
89
37
Sawyer and Timothy (1997) [4]
11
94
38
Girinsky et al. (2001) [5]
48
81
57
Haas et al. (2003) [6]
109
92
61
Hoskin et al. (2014) [7]
243
80
König et al. (2018) [8]
47
90
82
Trials